U.S. Approval Of Edwards Sapien Transcatheter Heart Valve Possible In 2009
This article was originally published in The Gray Sheet
Executive Summary
Edwards Lifesciences is on track to begin a U.S. pivotal trial in early 2007 for its Sapien transcatheter aortic heart valve, making FDA approval possible by late 2009, according to the company
You may also be interested in...
Edwards Redesigns PARTNER Trial, Pushes Back Sapien Approval Timeline
Edwards Lifesciences has reached a verbal agreement with FDA on an amended design for the PARTNER trial of its Sapien transcatheter aortic valve, the company announced during its Dec. 7 2007 investor conference
Edwards Redesigns PARTNER Trial, Pushes Back Sapien Approval Timeline
Edwards Lifesciences has reached a verbal agreement with FDA on an amended design for the PARTNER trial of its Sapien transcatheter aortic valve, the company announced during its Dec. 7 2007 investor conference
Edwards Set To Launch “Two-Trials-In-One” For Sapien Percutaneous Valve
Edwards Lifesciences will soon begin a 600-patient U.S. pivotal clinical trial for its Sapien transcatheter aortic replacement heart valve at Columbia University Medical Center and the Cleveland Clinic, the company says